Related references
Note: Only part of the references are listed.A gene expression-based model predicts outcome in chil-dren with intermediate-risk classical Hodgkin lymphoma
Rebecca L. Johnston et al.
BLOOD (2022)
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience
Fulvio Massaro et al.
HEMATOLOGICAL ONCOLOGY (2022)
Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study
Jianqiu Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2022)
Increased Production of B-Cell Activating Cytokines and Altered Peripheral B-Cell Subset Distribution during HIV-Related Classical Hodgkin Lymphoma
Raphael Lievin et al.
CANCERS (2022)
Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
Fulvio Massaro et al.
CANCERS (2022)
Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review
Vivek S. Radhakrishnan et al.
FRONTIERS IN ONCOLOGY (2022)
Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
Timothy J. Voorhees et al.
BLOOD ADVANCES (2022)
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
Pier Luigi Zinzani et al.
BLOOD ADVANCES (2022)
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE
Matthew G. Mei et al.
BLOOD (2022)
Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study
Ningjing Lin et al.
EUROPEAN JOURNAL OF CANCER (2022)
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
Ajay Major et al.
HAEMATOLOGICA (2022)
In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability
Naike Casagrande et al.
HAEMATOLOGICA (2022)
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience
Marina Moretti et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group
Rahul R. Parikh et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
Marie Jose Kersten et al.
HAEMATOLOGICA (2021)
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma
Pamela B. Allen et al.
BLOOD (2021)
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series
Annabel McMillan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response
Josefa Dela Cruz Chuh et al.
MABS (2021)
Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
Francois Laliberte et al.
TARGETED ONCOLOGY (2021)
A New Target for Hodgkin Lymphoma-Camidanlumab Tesirine
Narendranath Epperla et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)
Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma
Naike Casagrande et al.
CANCER LETTERS (2021)
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Ranjana H. Advani et al.
BLOOD (2021)
Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
Alex F. Herrera et al.
BLOOD ADVANCES (2021)
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
Yang Liu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL).
Yuqin Song et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma
Victor M. Orellana-Noia et al.
BLOOD ADVANCES (2021)
Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy
Chen-yu Wang et al.
ACTA PHARMACOLOGICA SINICA (2021)
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Yuqin Song et al.
LEUKEMIA (2020)
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study
David J. Straus et al.
BLOOD (2020)
Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study
Jonathon B. Cohen et al.
CANCER (2020)
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
Paul J. Broeckelmann et al.
JAMA ONCOLOGY (2020)
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
Huseyin Bekoz et al.
ANNALS OF HEMATOLOGY (2020)
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Nancy L. Bartlett et al.
BLOOD (2020)
Sintilimab as salvage treatment in an HIV patient with relapsed/refractory Hodgkin: a case report
Yang Shi et al.
ANNALS OF PALLIATIVE MEDICINE (2020)
KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure
Philippe Armand et al.
BLOOD ADVANCES (2020)
A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma
Lauren Shea et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies
Dennis Kirchhoff et al.
CANCERS (2020)
Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Alex F. Herrera et al.
BLOOD (2020)
Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series
Helen Ma et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)
Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment
Stephanie Sasse et al.
HAEMATOLOGICA (2019)
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
Philippe Armand et al.
BLOOD (2019)
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
Jeremy S. Abramson et al.
BLOOD (2019)
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation
Guillaume Manson et al.
EUROPEAN JOURNAL OF CANCER (2019)
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Robert Chen et al.
BLOOD (2019)
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
R. Garcia-Sanz et al.
ANNALS OF ONCOLOGY (2019)
Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management
Stephen M. Ansell
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting
Auayporn Nademanee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
Ann S. LaCasce et al.
BLOOD (2018)
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Craig H. Moskowitz et al.
BLOOD (2018)
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Alex F. Herrera et al.
BLOOD (2018)
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma
Robert Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H. Moskowitz et al.
BLOOD (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres
Stephen D. Smith et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
N. L. Bartlett et al.
ANNALS OF ONCOLOGY (2007)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)